(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are PAVmed, Groupon, and NeuBase Therapeutics .

The three biggest losers today are PAVmed, Predictive Oncology, and Opera Limited.

Winners today

1. PAVmed (PAVMW) – 105.67%

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.

NASDAQ ended the session with PAVmed rising 105.67% to $0.03 on Wednesday while NASDAQ slid 1.21% to $13,502.20.

Moving Average

PAVmed’s worth is way under its 50-day moving average of $0.21 and way below its 200-day moving average of $1.66.

More news about PAVmed.

2. Groupon (GRPN) – 13.86%

Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.

NASDAQ ended the session with Groupon jumping 13.86% to $4.85 on Wednesday, following the last session’s downward trend. NASDAQ slid 1.21% to $13,502.20, after two consecutive sessions in a row of losses, on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, Groupon has a trailing twelve months EPS of $-7.98.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -285.15%.

Volatility

Groupon’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.36%, a positive 0.32%, and a positive 5.40%.

Groupon’s highest amplitude of average volatility was 8.13% (last week), 6.07% (last month), and 5.40% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Groupon’s stock is considered to be overbought (>=80).

Revenue Growth

Year-on-year quarterly revenue growth declined by 20.7%, now sitting on 567.38M for the twelve trailing months.

Sales Growth

Groupon’s sales growth is negative 19.7% for the ongoing quarter and negative 13.2% for the next.

More news about Groupon.

3. NeuBase Therapeutics (NBSE) – 12.96%

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

NASDAQ ended the session with NeuBase Therapeutics jumping 12.96% to $3.05 on Wednesday while NASDAQ fell 1.21% to $13,502.20.

Earnings Per Share

As for profitability, NeuBase Therapeutics has a trailing twelve months EPS of $-18.53.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -93.46%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NeuBase Therapeutics ‘s stock is considered to be oversold (<=20).

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 61.5% and 56.2%, respectively.

Volatility

NeuBase Therapeutics ‘s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.63%, a negative 1.24%, and a positive 4.22%.

NeuBase Therapeutics ‘s highest amplitude of average volatility was 8.01% (last week), 4.48% (last month), and 4.22% (last quarter).

Moving Average

NeuBase Therapeutics ‘s value is way below its 50-day moving average of $3.44 and way under its 200-day moving average of $4.82.

More news about NeuBase Therapeutics .

4. Performance Shipping (PSHG) – 9.85%

Performance Shipping Inc., through its subsidiaries, provides shipping transportation services through its ownership of tanker vessels worldwide. It owned and operated five Aframax tanker vessels with a combined carrying capacity of 546,094 dwt. The company was incorporated in 2010 and is based in Athens, Greece.

NASDAQ ended the session with Performance Shipping rising 9.85% to $0.78 on Wednesday while NASDAQ dropped 1.21% to $13,502.20.

Earnings Per Share

As for profitability, Performance Shipping has a trailing twelve months EPS of $3.04.

PE Ratio

Performance Shipping has a trailing twelve months price to earnings ratio of 0.26. Meaning, the purchaser of the share is investing $0.26 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.88%.

Sales Growth

Performance Shipping’s sales growth for the current quarter is negative 45.3%.

Moving Average

Performance Shipping’s value is under its 50-day moving average of $0.79 and way under its 200-day moving average of $2.54.

More news about Performance Shipping.

5. NuCana plc (NCNA) – 8.72%

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

NASDAQ ended the session with NuCana plc rising 8.72% to $0.80 on Wednesday, following the last session’s upward trend. NASDAQ dropped 1.21% to $13,502.20, after two successive sessions in a row of losses, on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, NuCana plc has a trailing twelve months EPS of $-0.73.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.6%.

Yearly Top and Bottom Value

NuCana plc’s stock is valued at $0.80 at 17:32 EST, way under its 52-week high of $2.24 and way above its 52-week low of $0.62.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 100% and a negative 45.5%, respectively.

Volatility

NuCana plc’s last week, last month’s, and last quarter’s current intraday variation average was 2.49%, 0.54%, and 5.32%.

NuCana plc’s highest amplitude of average volatility was 4.31% (last week), 4.20% (last month), and 5.32% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NuCana plc’s stock is considered to be oversold (<=20).

More news about NuCana plc.

6. Nikola (NKLA) – 8.39%

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Nikola rising 8.39% to $1.43 on Wednesday while NASDAQ slid 1.21% to $13,502.20.

Earnings Per Share

As for profitability, Nikola has a trailing twelve months EPS of $-1.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -137.05%.

Volume

Today’s last reported volume for Nikola is 110986000 which is 155.43% above its average volume of 43449200.

Moving Average

Nikola’s worth is way above its 50-day moving average of $0.86 and way below its 200-day moving average of $2.42.

More news about Nikola.

7. Cronos Group (CRON) – 8.19%

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones brand in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

NASDAQ ended the session with Cronos Group jumping 8.19% to $1.85 on Wednesday while NASDAQ dropped 1.21% to $13,502.20.

Earnings Per Share

As for profitability, Cronos Group has a trailing twelve months EPS of $-0.41.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.69%.

Moving Average

Cronos Group’s value is above its 50-day moving average of $1.84 and way below its 200-day moving average of $2.47.

More news about Cronos Group.

8. Ocugen (OCGN) – 7.67%

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

NASDAQ ended the session with Ocugen jumping 7.67% to $0.55 on Wednesday, following the last session’s upward trend. NASDAQ dropped 1.21% to $13,502.20, after two successive sessions in a row of losses, on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, Ocugen has a trailing twelve months EPS of $-0.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -77.16%.

More news about Ocugen.

9. Catalyst Pharmaceuticals (CPRX) – 6.5%

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

NASDAQ ended the session with Catalyst Pharmaceuticals jumping 6.5% to $13.44 on Wednesday, following the last session’s upward trend. NASDAQ slid 1.21% to $13,502.20, after two consecutive sessions in a row of losses, on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.88.

PE Ratio

Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 15.27. Meaning, the purchaser of the share is investing $15.27 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.89%.

Moving Average

Catalyst Pharmaceuticals’s worth is under its 50-day moving average of $14.46 and way under its 200-day moving average of $15.32.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Catalyst Pharmaceuticals’s EBITDA is 4.48.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Catalyst Pharmaceuticals’s stock is considered to be oversold (<=20).

More news about Catalyst Pharmaceuticals.

10. OPKO Health (OPK) – 6.45%

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.

NASDAQ ended the session with OPKO Health jumping 6.45% to $1.65 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ slid 1.21% to $13,502.20, after two successive sessions in a row of losses, on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, OPKO Health has a trailing twelve months EPS of $-0.41.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.39%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

OPKO Health’s EBITDA is 1.6.

More news about OPKO Health.

Losers Today

1. PAVmed (PAVMZ) – -31.52%

NASDAQ ended the session with PAVmed falling 31.52% to $0.18 on Wednesday while NASDAQ dropped 1.21% to $13,502.20.

Yearly Top and Bottom Value

PAVmed’s stock is valued at $0.18 at 17:32 EST, way under its 52-week high of $0.26 and above its 52-week low of $0.18.

More news about PAVmed.

2. Predictive Oncology (POAI) – -14.85%

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

NASDAQ ended the session with Predictive Oncology falling 14.85% to $3.79 on Wednesday, after three sequential sessions in a row of gains. NASDAQ fell 1.21% to $13,502.20, after two consecutive sessions in a row of losses, on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, Predictive Oncology has a trailing twelve months EPS of $-7.94.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -92.54%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 23.7%, now sitting on 1.43M for the twelve trailing months.

Moving Average

Predictive Oncology’s value is under its 50-day moving average of $3.83 and way under its 200-day moving average of $6.51.

More news about Predictive Oncology.

3. Opera Limited (OPRA) – -13.75%

Opera Limited, together with its subsidiaries, provides mobile and PC web browsers. The company offers mobile browser products, such as Opera Mini, Opera for Android, and Opera Touch; PC browsers, including Opera for Computers and Opera GX; Opera News, a personalized news aggregation app; and Okash, a microfinance app. It operates in India, Ireland, Kenya, Russia, and internationally. The company was founded in 1996 and is headquartered in Oslo, Norway. As of January 13, 2021, Opera Limited (NasdaqGS : OPRA) operates as subsidiary of Kunlun Tech Limited.

NASDAQ ended the session with Opera Limited dropping 13.75% to $17.94 on Wednesday while NASDAQ dropped 1.21% to $13,502.20.

Earnings Per Share

As for profitability, Opera Limited has a trailing twelve months EPS of $0.4.

PE Ratio

Opera Limited has a trailing twelve months price to earnings ratio of 44.85. Meaning, the purchaser of the share is investing $44.85 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.35%.

More news about Opera Limited.

4. ShiftPixy (PIXY) – -12.45%

ShiftPixy, Inc., together with its subsidiaries, provides staffing solutions in the United States. It offers employment administrative services, such as payroll processing, human resources consulting, and workers' compensation administration and coverage. The Company also operates human resources information systems platform to assist in customer acquisition for the onboarding of new clients into the company's closed proprietary operating and processing information system. It primarily serves restaurant and hospitality service industries. The company was incorporated in 2015 and is headquartered in Miami, Florida.

NASDAQ ended the session with ShiftPixy dropping 12.45% to $2.32 on Wednesday while NASDAQ fell 1.21% to $13,502.20.

Earnings Per Share

As for profitability, ShiftPixy has a trailing twelve months EPS of $-82.63.

Volume

Today’s last reported volume for ShiftPixy is 94103 which is 65.4% above its average volume of 56891.

Revenue Growth

Year-on-year quarterly revenue growth declined by 56.1%, now sitting on 26.47M for the twelve trailing months.

More news about ShiftPixy.

5. ZoomInfo (ZI) – -9.26%

ZoomInfo Technologies Inc., through its subsidiaries, provides go-to-market intelligence and engagement platform for sales and marketing teams in the United States and internationally. The company's cloud-based platform provides information on organizations and professionals to help users identify target customers and decision makers, obtain continually updated predictive lead and company scoring, monitor buying signals and other attributes of target companies, craft messages, engage through automated sales tools, and track progress through the deal cycle. It serves enterprises, mid-market companies, and down to small businesses that operate in various industry verticals, including software, business services, manufacturing, telecommunications, financial services, retail, media and internet, transportation, education, hospitality, and real estate. ZoomInfo Technologies Inc. was founded in 2007 and is headquartered in Vancouver, Washington.

NASDAQ ended the session with ZoomInfo falling 9.26% to $24.05 on Wednesday, after two sequential sessions in a row of losses. NASDAQ slid 1.21% to $13,502.20, after two sequential sessions in a row of losses, on what was an all-around down trend trading session today.

Earnings Per Share

As for profitability, ZoomInfo has a trailing twelve months EPS of $0.23.

PE Ratio

ZoomInfo has a trailing twelve months price to earnings ratio of 104.54. Meaning, the purchaser of the share is investing $104.54 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.64%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ZoomInfo’s stock is considered to be overbought (>=80).

Revenue Growth

Year-on-year quarterly revenue growth grew by 24.4%, now sitting on 1.16B for the twelve trailing months.

Volume

Today’s last reported volume for ZoomInfo is 7276030 which is 34.81% above its average volume of 5397210.

More news about ZoomInfo.

6. Powerbridge Technologies Co., Ltd. (PBTS) – -9.03%

Powerbridge Technologies Co., Ltd. provides software application and technology solutions and services primarily in China. The company offers Powerbridge System Solutions, which include Trade Enterprise and Trade Compliance, as well as Import & Export Loan and Insurance Processing for customers to streamline their trade operations, trade logistics, and regulatory compliance. It also provides Powerbridge Software-as-a-Service solutions, which include Logistics Service Cloud and Trade Zone Operations Cloud, as well as Inward Processed Manufacturing Cloud, Cross-Border eCommerce Cloud, and Import & Export Loan and Insurance Processing Service Cloud; and Powerbridge Blockchain-as-a-Service that comprise Compliance Blockchain Services and Supply Chain Blockchain Services. The company serves international trade businesses and manufacturers, government agencies and authorities, and logistics service and other providers. It sells its solutions and services through its direct sales organization, indirect channel partners, and strategic government partners. Powerbridge Technologies Co., Ltd. was founded in 1997 and is headquartered in Zhuhai, China.

NASDAQ ended the session with Powerbridge Technologies Co., Ltd. dropping 9.03% to $1.41 on Wednesday, following the last session’s downward trend. NASDAQ dropped 1.21% to $13,502.20, after two consecutive sessions in a row of losses, on what was an all-around negative trend trading session today.

Earnings Per Share

As for profitability, Powerbridge Technologies Co., Ltd. has a trailing twelve months EPS of $-6.89.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -23.24%.

More news about Powerbridge Technologies Co., Ltd..

7. NeuroBo Pharmaceuticals (NRBO) – -8.48%

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.

NASDAQ ended the session with NeuroBo Pharmaceuticals falling 8.48% to $0.42 on Wednesday, after two successive sessions in a row of losses. NASDAQ dropped 1.21% to $13,502.20, after two successive sessions in a row of losses, on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, NeuroBo Pharmaceuticals has a trailing twelve months EPS of $-14.16.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -84.45%.

More news about NeuroBo Pharmaceuticals.

8. ENDRA Life Sciences (NDRA) – -8%

ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. It develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. The company also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

NASDAQ ended the session with ENDRA Life Sciences dropping 8% to $1.38 on Wednesday, following the last session’s downward trend. NASDAQ slid 1.21% to $13,502.20, after two sequential sessions in a row of losses, on what was an all-around down trend trading session today.

Earnings Per Share

As for profitability, ENDRA Life Sciences has a trailing twelve months EPS of $-4.24.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -195.52%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 54.2% and 57%, respectively.

More news about ENDRA Life Sciences.

9. OneSpan (OSPN) – -7.63%

OneSpan Inc., together with its subsidiaries, designs, develops, and markets digital solutions for identity, security, and business productivity worldwide. The company offers Trusted Identity Platform, a cloud-based platform to secure users, devices, and transactions across the digital journey; Intelligent Adaptive Authentication, a cloud-based solution that enables banks and other financial institutions to secure users, devices, and transactions; and Risk Analytics, a comprehensive anti-fraud solution. It also provides OneSpan Cloud Authentication, a cloud-based multifactor authentication solution that supports a range of authentication options, including biometrics, push notification, and visual cryptograms for transaction data signing, SMS, and hardware authenticators; OneSpan Identity Verification, which enables banks and financial institutions to verify the identity of remote applicants during the new digital account opening, lending, and financing application processes; Mobile Security Suite, a software development kit; and Mobile Authenticator Studio, a mobile authenticator that operates as a discrete mobile application. In addition, the company offers OneSpan Sign, which supports a range of e-signature requirements from simple to complex; Digipass hardware authenticators that supports authentication and digital signatures for applications running on PCs, tablets, and mobile phones; and authentication servers, which enables customers to administer a high level of access control. It sells its solutions through its direct sales force, as well as through distributors, resellers, systems integrators, and original equipment manufacturers. The company was formerly known as VASCO Data Security International, Inc. and changed its name to OneSpan Inc. in May 2018. OneSpan Inc. was founded in 1991 and is headquartered in Chicago, Illinois.

NASDAQ ended the session with OneSpan sliding 7.63% to $15.37 on Wednesday while NASDAQ slid 1.21% to $13,502.20.

Earnings Per Share

As for profitability, OneSpan has a trailing twelve months EPS of $-0.69.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.24%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 9.8%, now sitting on 224.17M for the twelve trailing months.

Moving Average

OneSpan’s worth is below its 50-day moving average of $15.56 and way above its 200-day moving average of $13.51.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is 50% and a drop 33.3% for the next.

Volume

Today’s last reported volume for OneSpan is 150465 which is 43.65% below its average volume of 267064.

More news about OneSpan.

10. Peloton (PTON) – -7.57%

Peloton Interactive, Inc. operates interactive fitness platform in North America and internationally. The company offers connected fitness products with touchscreen that streams live and on-demand classes under the Peloton Bike, Peloton Bike+, Peloton Tread, and Peloton Tread+ names. It also provides connected fitness subscriptions for various household users, and access to various live and on-demand classes, as well as Peloton Digital app for connected fitness subscribers to provide access to its classes. As of June 30, 2022, it had approximately 6.9 million members. The company markets and sells its interactive fitness products directly through its retail showrooms and at onepeloton.com. Peloton Interactive, Inc. was founded in 2012 and is headquartered in New York, New York.

NASDAQ ended the session with Peloton sliding 7.57% to $7.64 on Wednesday, after three sequential sessions in a row of losses. NASDAQ dropped 1.21% to $13,502.20, after two successive sessions in a row of losses, on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, Peloton has a trailing twelve months EPS of $-6.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -279.85%.

More news about Peloton.

Stay up to date with our winners and losers daily report